98. Eosinophilic gastrointestinal disease Clinical trials / Disease details
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000082-16-DE (EUCTR) | 21/01/2021 | 29/07/2020 | A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagus | A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis | Active eosinophilic esophagitis MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: ESO-101 Product Code: ESO-101 INN or Proposed INN: mometasone Other descriptive name: MOMETASONE FUROATE | EsoCap AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Phase 2 | Spain;Netherlands;Germany;Switzerland | ||
| 2 | EUCTR2020-000082-16-NL (EUCTR) | 29/10/2020 | 03/09/2020 | A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagus | A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis | Active eosinophilic esophagitis MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: ESO-101 Product Code: ESO-101 INN or Proposed INN: mometasone Other descriptive name: MOMETASONE FUROATE | EsoCap AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Phase 2 | Spain;Germany;Netherlands;Switzerland | ||
| 3 | NCT02113267 (ClinicalTrials.gov) | April 2014 | 10/4/2014 | Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study. | Treatment of Eosinophilic Esophagitis With Mometason Furoat Aerosol: a Randomised, Placebo-controled Phase II Study for Evaluation of Treatment Effect on Group Level Including Symtom Questionnaires | Eosinophilic Esophagitis | Drug: Mometasone furoate;Drug: Placebo | Mogens Bove | Vastra Gotaland Region | Terminated | 18 Years | N/A | All | 40 | Phase 2 | Sweden |